An observational study in Systemic Sclerosis, Gougerot Sjogren Syndrome and Sicca-Asthenia-Polyalgia Syndrome, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University Hospital, Clermont-Ferrand · Observational
Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modificat…PubMed 31189553 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.
Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 30th largest by enrollment of the 50 observational ones that give a count, is one of 4 that started in 2017, is one of 51 observational ones, and was the 43rd registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18–85 · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in France, United States, Argentina and 42 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18–64
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 28 · Phase 3 15
First in 2001; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is close to the median of 100 across 145 observational studies indexed under Scleroderma, Systemic.
Median enrollment 75 across the 81 interventional studies, 150 across the 50 observational. Of the 71 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 132 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 1 study filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
7 of the studies in Scleroderma, Systemic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT04356755University Hospital, ToulouseSubcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. | 2027-03 |
| NCT07888842Assistance Publique - Hôpitaux de ParisA Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status. | 2027-05 |
| NCT07543679Centre Hospitalier Universitaire de Saint EtienneObjective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis | 2027-05-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 132 studies in Scleroderma, Systemic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis. Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia). It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other). Several criteria have been validated to classify the SS but require a labial salivary gland biopsy, invasive act which complications can sometimes be reported (hematoma, lip sensory defect).
Several scores based on the evaluation of the ultrasound homogeneity of the salivary glands were developed but no studies have evaluated ultrasound abnormalities of salivary glands in patients with systemic sclerosis.
Descriptive explorative study of three population showing sicca symptoms (Systemic sclerosis, Gougerot-Sjogren syndrome, Sicca-Asthenia-Polyalgia syndrome).
Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).
Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.
20 systemic sclerosis, 40 Gougerot-Sjogren syndrome, 40 Sicca-Asthenia-Polyalgia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
Other: Ultrasonography
Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
Other: Ultrasonography
It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
Other: Ultrasonography
Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France). Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.
Jousse-Joulin ultrasonography score
Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated.
Time frame: the day of inclusion
Ultrasonography score equal or higher than 2 on at least one salivary gland
Time frame: the day of inclusion
Ultrasonography score equal or higher than 3 on at least one salivary gland
Time frame: the day of inclusion
Global ultrasonography score higher than 6/16
Time frame: the day of inclusion
Salivary glands area
Time frame: the day of inclusion
Ran from Mar 2017 to primary completion in Dec 2018, 21 months.
Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's 21 months is below that.
Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2019 → Dec 2018 and completion May 2019 → Feb 2019.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modificat…PubMed 31189553 ↗
Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M, Dubost JJ. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modificat…PubMed 31189553 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →